awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38222465-18D891DC-BDCB-4944-9A2C-F0B82F972958
Q38222465-18D891DC-BDCB-4944-9A2C-F0B82F972958
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38222465-18D891DC-BDCB-4944-9A2C-F0B82F972958
Risks and benefits of phase 1 clinical trial participation.
P2860
Q38222465-18D891DC-BDCB-4944-9A2C-F0B82F972958
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38222465-18D891DC-BDCB-4944-9A2C-F0B82F972958
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ab4ede11940e2b63fe4275f11e69b6c74bfbae42
P2860
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.